Cargando…
P839: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN SHOW IMPROVEMENTS IN D-DIMER NORMALIZATION AND DECREASE IN INCIDENCE OF THROMBOSIS
Autores principales: | Weitz, I., Al-Adhami, M., Min, J., Persson, E., Yeh, M., Savage, J., Dingli, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430914/ http://dx.doi.org/10.1097/01.HS9.0000846240.50953.6f |
Ejemplares similares
-
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal
hemoglobinuria
por: Wong, Raymond S.M.
Publicado: (2022) -
Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023) -
P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS
por: Kelly, Richard, et al.
Publicado: (2023) -
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022) -
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
por: Fishman, Jesse, et al.
Publicado: (2023)